Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment
Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company advancing novel small molecule therapeutics for immuno-oncology and hematological malignancies, announced…
AdvanCell Announces $18M MRFF Funding for Targeted Prostate Cancer Therapy
AdvanCell Announces $18M MRFF Funding for Targeted Prostate Cancer Therapy AdvanCell, a clinical-stage radiopharmaceutical company at the forefront of targeted cancer therapeutics, has received a significant boost from the Australian…
FDA Approves VYVGART Hytrulo Prefilled Syringe with ENHANZE for Self-Injection in gMG and CIDP
FDA Approves VYVGART Hytrulo Prefilled Syringe with ENHANZE for Self-Injection in gMG and CIDP In a major development for patients suffering from chronic neuromuscular autoimmune disorders, Halozyme Therapeutics, Inc. announced…
Vertex’s Paul Negulescu, Ph.D., Wins 2025 Gairdner Award for Cystic Fibrosis Breakthroughs
Vertex’s Paul Negulescu, Ph.D., Wins 2025 Gairdner Award for Cystic Fibrosis Breakthroughs In a landmark moment for both Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and the broader scientific community, Paul Negulescu,…
Bruker Enhances IR Biotyper® for Hospital Hygiene with NGS Reflex Testing
Bruker Enhances IR Biotyper® for Hospital Hygiene with NGS Reflex Testing At the ESCMID Global 2025 conference, Bruker’s Microbiology and Infection Diagnostics division made a major announcement regarding the expansion…
Amneal Pledges $1.5 Million to Aid Parkinson’s Patients in Honor of Awareness Month
Amneal Pharmaceuticals Commits $1.5 Million to Support Parkinson’s Disease Patients During Awareness Month In a powerful show of solidarity with the Parkinson’s community, Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), a global…
FDA Approves Opdivo and Yervoy Combo as First-Line Treatment for Advanced Liver Cancer
FDA Approves Opdivo and Yervoy Combo as First-Line Treatment for Advanced Liver Cancer In a significant advancement for liver cancer treatment, Bristol Myers Squibb (NYSE: BMY) has announced that the…
Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML)
Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML) Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing innovative therapeutics targeting diseases with high unmet…
Arcturus Gets FDA Fast Track for H5N1 mRNA Vaccine
Arcturus Therapeutics Secures FDA Fast Track Designation for ARCT-2304, a Next-Generation sa-mRNA Vaccine Targeting Pandemic Influenza A (H5N1) In a significant milestone for mRNA vaccine innovation, Arcturus Therapeutics Holdings Inc.…
Signios Bio Debuts with AI-Powered Multiomics Platform for Precision Medicine and Drug Discovery
Signios Biosciences Unveils Rebrand and Expands Vision as a Leading Multiomics and AI Bioinformatics Innovator in Precision Medicine In a bold step forward reflecting its evolution and expanded capabilities, Signios…
Avanzanite Bioscience Names Sotiris Botozis as Managing Director for Southern Europe
Avanzanite Bioscience Appoints Sotiris Botozis as Managing Director for Southern Europe Amid Strategic Expansion and Unprecedented Growth Avanzanite Bioscience BV, a rapidly growing player in the European life sciences and…
FDA Grants Full Approval to VITRAKVI for NTRK Fusion-Positive Tumors
FDA Grants Full Approval to Bayer’s VITRAKVI® (Larotrectinib), a Landmark TRK Inhibitor for Patients with NTRK Fusion-Positive Solid Tumors In a milestone for precision oncology, Bayer announced today that the…